New Age Alpha Advisors LLC Has $699,000 Position in Cencora, Inc. (NYSE:COR)

New Age Alpha Advisors LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2,538.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,113 shares of the company's stock after purchasing an additional 2,995 shares during the period. New Age Alpha Advisors LLC's holdings in Cencora were worth $699,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC boosted its position in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after acquiring an additional 46 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Cencora in the 4th quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC grew its position in Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Cencora during the 4th quarter worth about $33,000. Finally, WASHINGTON TRUST Co lifted its stake in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. Institutional investors own 97.52% of the company's stock.

Cencora Price Performance

Shares of Cencora stock traded down $10.07 during mid-day trading on Friday, reaching $279.29. 4,404,535 shares of the stock were exchanged, compared to its average volume of 1,469,415. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The company has a market cap of $54.16 billion, a price-to-earnings ratio of 39.73, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm has a 50-day simple moving average of $257.28 and a 200 day simple moving average of $242.65. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date was Friday, February 14th. Cencora's payout ratio is presently 31.29%.

Insider Activity

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now directly owns 317,913 shares in the company, valued at approximately $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI upped their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.